JUL 31, 2018 5:45 PM PDT

Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?

WRITTEN BY: Mauri Brueggeman

Researchers have been examining the loss of control over the DNA replication and cell proliferation process since it was connected to the development of cancer.  One of the most well-known and common traits of the disease in all types of cancer diagnoses is this this uncontrolled cellular replication and growth. 

In healthy cells, this process is carefully regulated and controlled through pathways and cellular checkpoints.  In a Nature Communications article published July 17, 2018, researchers identified a replication initiation determinant protein (RepID) that regulates replication through association of other proteins, drawing them directly to chromatin sites for replication initiation.  One of these proteins is a Culling-RING E3 ubiquitin ligase (CRL) which one of many CRLs.  CRL4 is recruited by RepID to chromatin in the very early stages of mitosis (cell cycle) prior to replication.  CRL4 acts to degrade CDT1, a protein that promotes replication at the appropriate time in the cell cycle.  Loss of CDT1 is the switch that tells a cell to only begin the DNA replication cycle once.  In addition to CRLs, a complex called SCF is also part of the cell cycle progression in mammals.  It, too, can facilitate degradation of chromatin proteins involved in regulation of mitosis and DNA replication later in the cell cycle (the S-phase).

In cases of RepID loss of expression or function, turning off that CDT1 switch is up to the SCF complex later in the cell cycle.  However, because the degradation was originated after DNA replication began, the cell re-replicated its DNA because there were higher levels of CDT1 associated with the chromatin.

Part of the SCF complex is a protein called SKP2.  This group of researchers treated the depleted RepID cancer cell cultures with a drug that inhibits SKP2, known as SZL-P1-41.  Their findings indicated that cells expressing intact RepID were not affected by the SKP2 inhibitor but cells with no RepID showed high sensitivity to SKP2 inhibition. The RepID knockout cells entered apoptosis and there were no surviving colonies in cell culture.  The researchers conclude that, “RepID expression levels might modulate the sensitivity of cancer cells to cullin-targeting drugs.”

Sources: Nature Communications, National Cancer Institute,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JAN 31, 2021
Genetics & Genomics
Targeting Aneuploidy in Cancer Cells
JAN 31, 2021
Targeting Aneuploidy in Cancer Cells
Cancer is typically related to problems in cells' genomes that lead to uncontrolled cell growth, and the formation of tu ...
FEB 10, 2021
Drug Discovery & Development
Genetics Affect Response to Cancer Immunotherapy
FEB 10, 2021
Genetics Affect Response to Cancer Immunotherapy
Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind ...
FEB 18, 2021
Cell & Molecular Biology
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
FEB 18, 2021
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
Researchers may have identified a new treatment target for a deadly form of brain cancer. Inhibiting an enzyme called PR ...
MAR 16, 2021
Cancer
Does exposure to propylparaben during preganancy increase risk of breast cancer?
MAR 16, 2021
Does exposure to propylparaben during preganancy increase risk of breast cancer?
A concerning new study suggests that exposure during pregnancy to low doses of a common chemical preservative called pro ...
MAR 19, 2021
Cancer
What does RNA editing do to the immune system?
MAR 19, 2021
What does RNA editing do to the immune system?
A recent study published in the journal Nature Communications from the University of Colorado Cancer Center explores new ...
APR 12, 2021
Cancer
Using antibodies to treat melanoma
APR 12, 2021
Using antibodies to treat melanoma
New research presented at the American Association of Cancer Research (AACR) virtual annual meeting this week from the Y ...
Loading Comments...